Literature DB >> 25757842

Sporadic meningioangiomatosis with and without meningioma: analysis of clinical differences and risk factors for poor seizure outcomes.

Chao Zhang1, Yao Wang, Xiu Wang, Jian-Guo Zhang, Jing-Jun Li, Wen-Han Hu, Kai Zhang.   

Abstract

BACKGROUND: Meningioangiomatosis (MA) is a rare cerebral lesion. Sporadic MA occasionally combines with meningioma (MA-M). The aim of the present study was to clarify whether MA-M and pure MA have clinical differences and to determine risk factors for unsatisfactory seizure outcomes in sporadic MA.
METHODS: We reported 14 sporadic MA cases in our center and conducted a literature review. We compared the demographic, clinical, imaging, electrophysiological and pathological features and surgical outcomes. Logistic regression analysis was performed to evaluate the risk factors for poor seizure outcomes.
RESULTS: MA-M cases showed a more prominent male predilection (4.2 times vs. 1.6 times, p = 0.04), a shorter duration of symptoms (2.8 ± 0.8 years vs. 5.2 ± 0.6 years, p = 0.02), and a lower seizure incidence (53.6 % vs. 89.3 %, p < 0.001) as compared to pure MA. A gyriform alteration on imaging was exclusively associated with pure MA. The Ki-67 was higher in the meningioma component than in the MA component in MA-M (1.2 ± 0.3 % vs. 6.1 ± 1.1 %, p < 0.001). Lesions located in the temporal lobe predicted poor seizure outcomes (p = 0.02, OR = 4.4, 95 % confidence interval, 1.24-15.89).
CONCLUSION: Clinical differences may be caused by the different biological natures. MA-M seems to be a neoplastic lesion, while pure MA seems to be a non-neoplastic lesion. Long-term follow-up is required for MA-M. Because the coexistence of hippocampal sclerosis may explain the poor seizure outcomes of MA located in the temporal lobe, it is important to identify underlying hippocampal sclerosis and to perform complete resection.

Entities:  

Mesh:

Year:  2015        PMID: 25757842     DOI: 10.1007/s00701-015-2375-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Progressive diffuse meningioangiomatosis: Response to bevacizumab treatment.

Authors:  Shlomit Yust-Katz; Gregory Fuller; Suzana Fichman-Horn; Natalia Michaeli; Edna Inbar; Judith Lukman; Dror Limon; Israel Steiner; Tali Siegal
Journal:  Neurology       Date:  2016-03-30       Impact factor: 9.910

2.  Non-meningothelial meningeal tumours with meningioangiomatosis-like pattern of spread.

Authors:  J B Iorgulescu; S Ferris; A Agarwal; S Casavilca Zambrano; D A Hill; R Schmidt; A Perry
Journal:  Neuropathol Appl Neurobiol       Date:  2018-04-10       Impact factor: 8.090

3.  Molecular Alterations in Meningioangiomatosis Causing Epilepsy.

Authors:  Antonio Dono; Azim Z Pothiawala; Cole T Lewis; Meenakshi B Bhattacharjee; Leomar Y Ballester; Nitin Tandon
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.685

4.  Magnetic Resonance Spectroscopy May Help Diagnose Sporadic Meningioangiomatosis Associated With Meningioma: A Case Report.

Authors:  Linfeng Liu; Feng Liang
Journal:  Front Neurol       Date:  2022-07-11       Impact factor: 4.086

5.  Sporadic Meningioangiomatosis: A Series of Three Pediatric Cases.

Authors:  Raja Anand; Richard J Garling; Janet Poulik; Marko Sabolich; Dylan J Goodrich; Sandeep Sood; Carolyn A Harris; Abilash Haridas
Journal:  Cureus       Date:  2017-09-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.